Press coverage about Flex Pharma (NASDAQ:FLKS) has trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.3262334167594 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

FLKS has been the subject of several recent research reports. Zacks Investment Research downgraded Flex Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Roth Capital initiated coverage on Flex Pharma in a report on Thursday, September 7th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $10.00 price objective on shares of Flex Pharma in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $9.55.

Flex Pharma (NASDAQ FLKS) opened at $4.18 on Monday. Flex Pharma has a 52 week low of $2.68 and a 52 week high of $7.10.

Flex Pharma (NASDAQ:FLKS) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.06. Flex Pharma had a negative return on equity of 71.39% and a negative net margin of 2,655.19%. The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.47 million. equities analysts expect that Flex Pharma will post -2.38 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/flex-pharma-flks-given-daily-media-impact-rating-of-0-23/1715234.html.

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Insider Buying and Selling by Quarter for Flex Pharma (NASDAQ:FLKS)

Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.